GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (NAS:FBLG) » Definitions » Institutional Ownership

FibroBiologics (FibroBiologics) Institutional Ownership : 0.08% (As of May. 23, 2024)


View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, FibroBiologics's institutional ownership is 0.08%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, FibroBiologics's Insider Ownership is 0.39%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, FibroBiologics's Float Percentage Of Total Shares Outstanding is 81.13%.


FibroBiologics Institutional Ownership Historical Data

The historical data trend for FibroBiologics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics Institutional Ownership Chart

FibroBiologics Historical Data

The historical data trend for FibroBiologics can be seen below:

2024-03-31 2024-04-30
Institutional Ownership 0.05 0.08

FibroBiologics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


FibroBiologics (FibroBiologics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598
FibroBiologics Inc is an early-stage, cell therapy company. Its primary focus is the initiation and progression of preclinical studies and clinical-stage FDA trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing, and other diseases.

FibroBiologics (FibroBiologics) Headlines